AzTrials
AzTrials

Chronic RhinosinusitisPhase 4HVSINCT01575223

Saline Irrigation After Surgery in Patients With Chronic Sinusitis

A Phase 4 study testing NeilMed sinus rinse and Salinex in people with Chronic Rhinosinusitis, run by Samuel Lunenfeld Research Institute, Mount Sinai Hospital at 4 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Purpose: To determine if high volume saline nasal irrigation (HVSI), (NeilMed® Sinus Rinse™) offers a benefit over low volume saline irrigation (LVSI), (Salinex®) in the early post-operative management in patients with chronic rhino sinusitis. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Chronic Rhinosinusitis
What is being tested?
NeilMed sinus rinse and Salinex
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
86 participants
Where
4 sitesCanada
Study dates
Mar 2012to Apr 2014
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Documented diagnosis of unilateral or bilateral CRS
  • Documented failed medical treatment of CRS
  • Eighteen (18) to sixty-five (65) years of age
  • Planned ESS for the treatment of CRS
  • Able to read and understand English

Who cannot join

  • Pregnant
  • Cystic Fibrosis
  • Diagnosed immotile cilia syndrome
  • Diagnosed immunodeficiency syndrome
  • Diagnosed fungal sinusitis
  • Sinonasal tumours or obstructive lesions

Trial locations and contacts

4 sites in 1 country.

Canada4 sites
  • University of Calgary Otolaryngology - Head & Neck Surgery

    Calgary, Alberta, T5J 3E4

  • Western University Dept. of Otolaryngology - Head & Neck Surgery

    London, Ontario, N6A 3K7

  • Ottawa University Otolaryngology - Head & Neck Surgery

    Ottawa, Ontario, K1Y 4E9

  • Mount Sinai Hospital

    Toronto, Ontario, M5G 2N2

Other trials in Canada

About this study

Official title: The HVSI STUDY: High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial

Purpose: To determine if high volume saline nasal irrigation (HVSI), (NeilMed® Sinus Rinse™) offers a benefit over low volume saline irrigation (LVSI), (Salinex®) in the early post-operative management in patients with chronic rhino sinusitis.

Read the detailed description

Background: Chronic Rhinosinusitis (CRS) is a common inflammatory condition of the upper respiratory tract lasting more than 8 to 12 weeks. Major symptoms include facial congestion/fullness, facial pain/pressure, nasal obstruction/blockage, purulent nasal drainage, and reduction or loss of smell. The diagnosis must include two major symptoms and either endoscopic evidence of polyps, edema or mucopurulent discharge from the middle meatus and/or CT changes in the mucosa of sinuses or osteomeatal complexes.1

CRS has an estimated prevalence of 5% in the Canadian population2, and up to 16% in some adult populations in the United States.3 Sinusitis is associated with a major societal health care burden, costing billions of dollars a year in North America.4,5 The medical treatment of CRS includes topical saline and corticosteroid sprays, systemic steroids and antimicrobials. Specifically, saline nasal irrigation (SNI) is a safe, nonpharmacologic treatment, and an important and efficacious component in the management of CRS.6,7 SNI can vary by concentration (e.g. hypertonic, isotonic, hypotonic) and device (e.g. bulb syringe, nasal mist, squeeze bottle).

The Mayo Clinic recently reviewed major expert consensus guidelines on the medical treatment of CRS.8 Although they recognized an overall paucity of controlled trials for any medical treatment, and a lack of a consensus or algorithm in the treatment of CRS, there is an overall consensus agreement of the use for SNI in this population. In this review, there was no mention of treatment of CRS in postoperative period, and no recommendation of what type of SNI is best.

Few studies examine various SNI formulations in the postoperative period. These were highlighted by Canadian authors in a recent exhaustive review of SNI in sinusitis.9 Three studies, all greater than 15 years old, include formulations that are not currently in popular use, or even available in North America.10-12 These did show that pressurized jets or sprays of seawater were more effective than nasal drops. More recently, Harvey et al. examined how irrigation is delivered and retained in the sinus, using more common devices.13,14 In a cadaveric model, they compared HVSI to LVSI devices and found a greater delivery (p<..02) in the former. To date there are no studies comparing HVSI to LVSI, using subjective patient benefit and objective endoscopic measure outcomes, in the postoperative CRS patient.

One study did examine two different SNI devices in the management of CRS.15 The authors recruited 150 subjects with CRS in the primary care setting, and randomized them to two weeks of SNI with a bulb syringe, SNI with a nasal irrigation pot, and a control group of reflexology massage.15 Hypertonic saline was used in both treatment groups. Subjective questionnaires were administered at baseline and at the end of the study period. Both groups significantly improved, with no significant difference between the two SNI devices. Patients equally preferred the two devices.

Popular HVSI and LVSI formulations with patients and physicians are NeilMed® Sinus Rinse™ and Salinex®, respectively. These are two examples of positive pressure treatments,13 which have enjoyed widespread usage in North America preceding sufficient evidence-based medicine demonstrating safety and efficacy. This is likely because topical saline sprays are considered safe; they do not require a prescription, and perhaps most importantly the massive marketing campaign surrounding SNI devices. SNI devices have received significant news coverage and appearances on major television shows, including the Oprah Winfrey Show, the New York Times, and numerous YouTube videos.16 Purpose: The authors hypothesize that there is an advantage of HVSI over LVSI. The mechanical effect of high volume irrigation helps ensure that a larger surface area of sinonasal mucosa is debrided and cleansed.

The aim of this study is to determine if there is a clinical benefit of HVSI over LVSI in the postoperative period in patients with CRS. This information would help otolaryngologists, family physicians, and other health care professionals recommend the best SNI device for their patients with CRS. It would also provide a much-needed prospective and controlled trial in the evidence for SNI in CRS in the post-operative period.

Population/Procedure: This is a multicenter, randomized, single blind, controlled prospective study evaluating the subjective and objective outcomes of HSVI versus LSVI in patients who have ESS for CRS. One month postoperative scores will be compared to preoperative scores. The expected total number of patients to be enrolled in this study is approximately 100, with a planned completion time of one year.

At our institution, ten patients who are offered endoscopic sinus surgery (ESS) for CRS will be approached for study participation.

Being tested
NeilMed sinus rinse, Salinex
Keywords
saline irrigation, chronic rhinosinusitis, endoscopic sinus surgery, high volume saline irrigation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NeilMed sinus rinseDevice

    High volume saline irrigation

  • SalinexDevice

    Low volume saline irrigation

Study groups in NCT01575223
Study groupRoleWhat they receive
High volume saline irrigationActive comparatorPatients in this group will receive high volume saline irrigation (NeilMed sinus rinse)
Receives: Device: NeilMed sinus rinse
PlaceboPlacebo comparatorPatients in this group will receive low volume saline irrigation (Salinex)
Receives: Device: Salinex

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sinonasal Outcomes Scale (SNOT-22)

    Subjective scale, completed by patient. Validated scale for chronic sinusitis.

    Measured: One month post-operatively

  2. Lund MacKay score

    Objective scale, validated, completed by investigator. Preoperative CT scan is scored based on degree of sinus opacification (0-24).

    Measured: 1 month postoperatively

  3. Nasal and Sinus Symptom Score (NSS) - Subjective scale

    A subjective scale, filled out by the patient, specific to symptoms of sinusitis.

    Measured: 1 month post-operatively

  4. Perioperative Sinus Endoscopy scale (POSE)

    Objective scale, completed by treating physician, to assess sinonasal contents endoscopically. Validated scale.

    Measured: 1 month post-operatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Apr 2012 (estimated)
  2. Study startMar 2012
  3. Primary completionApr 2014
  4. Study completionApr 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
86 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01575223
Sponsor's protocol ID
HVSI-001
Acronym
HVSI
Status last verified
Apr 2014
First submitted
1 Apr 2012
Last updated
23 Apr 2014
Results posted
No
Data monitoring committee
No

Publications

  • Desrosiers M, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, Ciavarella A, Doyle PW, Javer AR, Leith ES, Mukherji A, Robert Schellenberg R, Small P, Witterick IJ. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2011 May;40 Suppl 2:S99-193. English, French.

    PubMed 21658337
  • Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope. 2003 Jul;113(7):1199-205. doi: 10.1097/00005537-200307000-00016.

    PubMed 12838019
  • Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl. 2004 May;193:3-5. doi: 10.1177/00034894041130s502.

    PubMed 15174752
  • Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M, Josephs S, Pung YH. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):408-14. doi: 10.1016/s0091-6749(99)70464-1.

    PubMed 10069873
  • Harvey RJ, Debnath N, Srubiski A, Bleier B, Schlosser RJ. Fluid residuals and drug exposure in nasal irrigation. Otolaryngol Head Neck Surg. 2009 Dec;141(6):757-61. doi: 10.1016/j.otohns.2009.09.006.

    PubMed 19932850

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing NeilMed sinus rinse and Salinex in people with Chronic Rhinosinusitis, run by Samuel Lunenfeld Research Institute, Mount Sinai Hospital at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sinonasal Outcomes Scale (SNOT-22) (time frame: One month post-operatively). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01575223, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in